The Pharma Data

JANUARY 5, 2021

Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins. Again, the goal was to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases.

RNA 52

RNA Protein Bioavailability DNA 52

Delveinsight

AUGUST 10, 2020

Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of IPF and SSc-ILD. Boehringer Ingelheim is worth mentioning here, as it is presenting key posters and studies on Ofev’s SENSCIS Trial and INBUILD Trial. Ofev (Nintedanib) Facts. billion.

Drugs 52

Drugs Trials Bioavailability FDA Approval 52

Roots Analysis

JANUARY 28, 2024

By analyzing this data, healthcare organizations can identify patterns and trends, predict patient outcomes, and develop personalized treatment plans. Throughout her career, Jayita has contributed to over six syndicate market research reports, covering a wide range of trending domains.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

The Pharma Data

DECEMBER 3, 2020

(TWO: 4162) announced today that it has entered into a Collaboration and License Agreement with UK-based Sentinel Oncology Limited for advancing the new drug development of SOL-578 , a Checkpoint Kinase 1 (Chk1) inhibitor, under which PharmaEngine will fund the IND enabling studies for SOL-578. ” said Yufang Hu , Ph.D.,

Licensing 52

Licensing Licensing Bioavailability DNA 52

Roots Analysis

MAY 21, 2024

In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40